Back to search
FDAFDA · Food and drugs·Recall number D-0939-2017

Clindamycin Injection USP; 300 mg/2 mL (150 mg/mL). 2 mL Single-dose ADD-VANTAGE Vial, Rx Only, Manufactured for Alvogen, Inc., Pine Brook, NJ 07058, NDC 47781-462-69

Published July 12, 2017 · Recall initiated: June 16, 2017

Summary

FDA records drug Class II recall D-0939-2017, published July 12, 2017 and initiated June 16, 2017. Recalling firm: Alvogen, Inc; Status: Terminated; Reported quantity: 5,100 2 mL vials; Lot: Lot: 73-154-EV; Exp. 12/31/17. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Alvogen, Inc
Distributor
Nationwide
Lot
Lot: 73-154-EV; Exp. 12/31/17
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Clindamycin Injection USP; 300 mg/2 mL (150 mg/mL). 2 mL Single-dose ADD-VANTAGE Vial, Rx Only, Manufactured for Alvogen, Inc., Pine Brook, NJ 07058, NDC 47781-462-69 recalled?

Yes. FDA published recall D-0939-2017 on July 12, 2017. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Press Release